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Objectives. Changes in cardiovascular risk factors
with menopausal status are difficult to study, owing
to the high correlation of menopausal status with
age. Therefore we examined cardiovascular risk
factors in a meticulously selected population in
which the contrast in oestrogen status between pre-
and postmenopausal women of the same age was
maximized.
Design. Risk factors were compared in 93 pre-
menopausal and 93 postmenopausal women who
were matched on age (range 43±55 years).
Setting. The women were selected from respondents
to a mailed questionnaire about the menopause,
which was sent to all women aged 40±60 years in
the Dutch town of Zoetermeer (n = 12 675; re-
sponse 54%).
Subjects. Postmenopausal women who were at least
3 years after menopause or whose menses had
stopped naturally before age 48 were age-matched
with premenopausal women with regular menses
and without menopausal complaints.
Results. Compared to premenopausal women,
postmenopausal women had significantly increased
levels of total cholesterol (10.0%, 95% confidence
interval 5.1±14.0), low density lipoprotein (LDL)
cholesterol (14.0%, 6.9±19.9), and apolipoprotein B
(8.2%, 0.6±15.5). The difference was present within
3 years after onset of menopause and did not show a
trend towards an increase with the number of
postmenopausal years. No differences were found in
high density lipoprotein (HDL) cholesterol, triglycer-
ides, apolipoprotein A1, blood glucose, insulin, body
mass index, waist-to-hip ratio, and systolic and
diastolic blood pressure.
Conclusions. The results of this study add to the
evidence that total cholesterol, LDL cholesterol and
apolipoprotein B are the primary cardiovascular risk
factors affected by menopause.
Keywords: apolipoproteins, cardiovascular disease,
cholesterol, insulin, menopause, risk factor.
Introduction
The incidence of cardiovascular disease in women
rises sharply after middle age. Although results of
large follow-up studies are inconsistent, menopause
is thought to be a major determinant of this increase
[1±3]. The mechanism through which menopause
exerts its effect on the cardiovascular system is still
unknown. Increased levels of serum total cholesterol
after cessation of menses have been found in most
studies on menopause and risk factors [4±16].
Inconsistent results, however, have been reported
with respect to HDL cholesterol [8±10, 12±14, 17],
apolipoproteins [7, 8, 12, 16±18], blood pressure
[4±6, 8, 9, 17 , 19±22], waist-to-hip ratio [23,
24] and insulin [25±27]. A difficulty with studying
the effects of menopause is the high correlation
between menopausal status and age. Studies that
included women in a broad age range may not be
able to validly remove the confounding effect of age
[13, 16, 19, 24]. Studies in a restricted age range
around the menopause will include premenopausal
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women who have irregular menses and postmeno-
pausal women who only recently passed meno-
pause, which reduces the contrast in oestrogen
status [17, 21].
In the present study, we examined the relation-
ships between natural menopause and several
atherogenic factors in a highly selected population
in which the contrast in oestrogen status between
pre- and postmenopausal women of the same age
was maximized.
Materials and methods
Study population
Selection of participants in this study was aimed at
maximizing the contrast in oestrogen status, in pre-
and postmenopausal women of the same age
(Fig. 1). A questionnaire, including questions about
menopausal status, medical history, medication use,
and smoking behaviour, was sent by mail to all
women aged 40±60 years and living in the town of
Zoetermeer, The Netherlands (n = 12 675). The
response rate was 54%. Selection of pre- and
postmenopausal women was based on the ques-
tionnaire. Women with a hysterectomy and/or uni-
or bilateral ovariectomy and women with missing
information on type or date of menopause (n = 233)
were excluded from the study population
(n = 1551). Women were considered pre-
menopausal if they had had one or more bleedings
in the past 12 months (n = 3829). Premenopausal
women who reported no longer having monthly
bleedings (n = 938) and women who reported the
presence of climacteric symptoms, defined as per-
spiration and/or hot flushes (n = 1645) were
excluded. Furthermore, premenopausal women
who reported use of hormone replacement therapy
or use of oral contraceptives within 6 months prior
to the clinical examination were excluded
(n = 423). The total number of premenopausal
women excluded for the above mentioned reasons
was 2191, leaving 1638 eligible premenopausal
women.
Women were considered to have had natural
menopause if their menses had ceased naturally for
at least 12 months (n = 1242). Postmenopausal
women who reported a history of hormone re-
placement therapy for over 6 months or use of
female hormones within 6 months prior to the
clinical examination and women who reported
cessation of bleedings immediately upon stopping
hormones were excluded (n = 241). The total
number of postmenopausal women excluded, in-
cluding those with missing values on hormone use
was 284, leaving 958 eligible postmenopausal
women. Of these women, we additionally excluded
women reporting diabetes mellitus (13; 0.8% pre-
menopausal vs. 16; 1.7% postmenopausal women),
use of antihypertensive medication (31; 1.9% vs. 35;
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12675 source population
6845 respondents to
mailed questionnaire (54%)
1638 eligible premenopausal women1 958 eligible postmenopausal women2
AGE MATCHING
424 women matched
Addditionally excluded3 140
Refused 62
Not reached 36
93 premenopausal women 93 postmenopausal women
Fig. 1 Schematic presentation of
the selection procedure of the study
population. (1) Eligible women
with regular menses and no
climacteric symptoms, who did not
use hormone replacement therapy
or oral contraceptives in the past
6 months. Subsequently women
who smoked, who had diabetes
mellitus or used antihypertensive
or cholesterol lowering drugs were
excluded. (2) Eligible women whose
menses had ceased naturally more
than 12 months ago and who had
not used hormone replacement
therapy. Subsequently women who
smoked, who had diabetes mellitus
or used antihypertensive or
cholesterol lowering drugs were
excluded. (3) Women who no
longer fulfilled the criteria at the
moment of examination were
excluded.
3.7%), use of cholesterol-lowering drugs (3; 0.2% vs.
20; 2.1%) and current smoking of 5 or more
cigarettes per day (302; 18.4% vs. 218; 22.8%).
Pre- and postmenopausal women were matched
on age, whilst maximizing the contrast in oestrogen
status. Postmenopausal women who were at least
3 years after menopause or whose menses had
stopped at least 3 years before the average age of
menopause (51 years) were age-matched with pre-
menopausal women with a regular menses and
without menopausal complaints. If it was not
possible to find a match within the same year of
age, a match was taken from an adjacent year. If
one of a matched pair was unwilling to participate a
new match was sought. Women were invited for
study participation on average 15 months after
return of the questionnaire. Out of 424 invited
women, 140 were excluded because they no longer
fulfilled the inclusion criteria (regular menses, no
climacteric symptoms, no hormone replacement
therapy or cardiovascular disease) or no proper
replacement match could be found. Sixty-two
women (15%) were unwilling to participate and
36 could not be reached. This left 93 pre- and 93
postmenopausal women, aged 43±55 years, who
participated in the study. All women gave written
informed consent, and the study was approved by
the medical ethical committee of the Erasmus
University Medical School.
Measurements
During a visit at the research centre, a medical
history was taken by a physician. Height, weight,
and waist and hip circumference were measured
with indoor clothes without shoes. Body mass index
(weight divided by height squared) and waist-to-hip
ratio were computed. Alcohol drinking habits and
cigarette smoking history were obtained by a
standardized questionnaire. Blood pressure was
assessed four times at the right upper arm after a
5 min rest in the supine position, with a Dinamap
automatic blood pressure recorder (Critikon, Tampa,
Florida, USA) and the mean was used in the
analyses. Venous blood samples were drawn from
each subject after a 12-h fast. The samples were
stored at ± 80 8C, and subsequently serum para-
meters were determined using a Kone Specific
Analyser (Kone Instruments, Espoo, Finland). Total
cholesterol was measured with an automated
enzymatic method [28], using the CHOD-PAP High
Performance reagent kit from Boehringer Mann-
heim (Germany). HDL cholesterol was measured by
the phosphotungstate method according to Burstein
[29] with a minor modification as described by
Grove [30]. The overall coefficients of variation for
total cholesterol and HDL cholesterol were 2.9% and
3.7%, respectively. LDL cholesterol was computed
with the Friedewald formula [31]. Serum triglycer-
ides were determined by using a reagent kit from
Boehringer Mannheim (Germany) after enzymatic
hydrolysis of the triglycerides with subsequent
determination of liberated glycerol by colourimetry.
No correction was made for serum free glycerol. The
overall coefficient of variation of this method did not
exceed 3.2%. Apolipoprotein A1 and B were
measured by an automated turbidimetric immuno-
assay using the reagent kits of Orion Diagnostics
(Espoo, Finland). Glucose was enzymatically deter-
mined by the Hexokinase method (Instruchemie,
Hilversum, The Netherlands). Serum insulin was
determined by Metric assay (Biosource Diagnostics,
Fleuris, Belgium). This assay has no cross-reactivity
with either pro-insulin or C-peptide.
Statistical analysis
Analysis of covariance was used to compare
characteristics of pre- and postmenopausal women,
with adjustment for age. Since the distribution of
insulin was highly skewed, it was natural-log
transformed for the analyses. Differences in frequen-
cies of smoking status and alcohol drinking were
tested by the Chi-square test. Differences in risk
factors between pre- and postmenopausal women
were expressed as percentages, and confidence
intervals for these percentages were calculated. If a
woman could not recall the exact date of onset of
menopause, but only the year, the date of meno-
pause was approximated and set on the first of July
of that year.
For the risk factors shown to differ significantly
between pre- and postmenopausal women, addi-
tional analysis were performed. The age-adjusted
means of these risk factors were calculated within
three groups of postmenopausal women defined
according to the number of postmenopausal years:
1.0±2.9 (n = 23), 3.0±6.0 (n = 39) and $6.0
(n = 31). A new ordinal variable was created,
comprising the values 1, 2, and 3, corresponding
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with the three categories of postmenopausal years.
The relationship between the risk factors and time
since menopause was estimated using linear regres-
sion analysis, with the ordinal variable as the
dependent variable.
Results
The number of postmenopausal years was on
average 5.4 (SD = 3.0), and ranged from 1.3 to
12.8. The postmenopausal women were slightly
older (mean 51.1, range 43.3±54.7) than the
premenopausal women (mean 50.6, range 44.1±
55.3) (Table 1). The group means of height, weight,
body mass index, waist-to-hip ratio, and alcohol
consumption showed no significant differences
(Table 1). Percentages of current smokers and ex-
smokers did not differ significantly between the
groups.
Significantly higher levels of serum total choles-
terol, LDL cholesterol and apolipoprotein B were
found in postmenopausal women compared with
premenopausal women, after adjustment for age
(Table 2). Levels of HDL cholesterol, triglycerides,
apolipoprotein A1, blood glucose, insulin, and
systolic and diastolic blood pressure were not
significantly different between the two groups.
Additional adjustment for body mass index, waist-
to-hip ratio, cigarette smoking and alcohol con-
sumption influenced the results only slightly. No
significant linear trend with number of postmeno-
pausal years was observed for the lipids, apolipo-
proteins levels and insulin levels, after adjustment
for age (Fig. 2).
Discussion
In the present study we found that mean levels of
serum total cholesterol, LDL cholesterol and apoli-
poprotein B were significantly higher in postmeno-
pausal women than in premenopausal women of the
same age. These higher levels were established
within 3 years after the onset of menopause and
did not change over postmenopausal time. Levels of
triglycerides, HDL cholesterol, apolipoprotein A1,
blood glucose, insulin, body mass index, waist-to-hip
ratio and systolic and diastolic blood pressure, were
not significantly associated with natural meno-
pause.
In studying the effect of menopause, age is an
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Table 1 General characteristics of pre- and postmenopausal
women
Premenopausal
(n = 93)
Postmenopausal
(n = 93)
Mean (SD)
Age (years) 50.6 (2.4) 51.1 (2.2)
Mean (SD)a
Height (cm) 166.8 (5.7) 165.6 (7.3)
Weight (kg) 68.8 (11.1) 68.6 (11.5)
Body Mass Index (kg m22) 24.7 (3.8) 25.0 (4.1)
Waist-to-hip ratio 0.77 (0.05) 0.77 (0.05)
Alcohol (grams per week) 45 (57.0) 45 (57.1)
Percentage (n)
Current smoking (%)b 6 (6) 6 (6)
Past smoking (%)b 42 (39) 39 (36)
aAdjusted for age. bSubjects who smoked five or more cigarettes
per day were excluded from study participation.
Table 2 Risk factors for cardiovascular disease in premenopausal and postmenopausal women
Mean (SE)a
Premenopausal
(n = 93)
Postmenopausal
(n = 93)
Difference
(%)
95% confidence interval
for the percentage difference
Total cholesterol (mmol L21) 5.89 (0.10) 6.48 (0.10)** 10.0% (5.1; 14.0)
LDL cholesterol (mmol L21) 3.78 (0.09) 4.32 (0.09)** 14.0% (6.9; 19.9)
HDL cholesterol (mmol L21) 1.58 (0.04) 1.64 (0.04) 3.7% (±2.9; 10.3)
Triglycerides (mmol L21) 1.16 (0.06) 1.16 (0.06) 0% (±13.5; 13.9)
Apolipoprotein A1 (mg dL21) 1.53 (0.03) 1.56 (0.03) 1.9% (±3.8; 8.0)
Apolipoprotein B (mg dL21) 0.89 (0.03) 1.06 (0.03)* 8.2% (0.6; 15.5)
Glucose (mmol L21) 5.56 (0.06) 5.55 (0.06) ±0.01% (±2.9; 2.6)
Insulin (picomol L21)b 45.7 (1.05) 44.9 (1.05) ±1.8% (±11.2; 14.8)
Systolic blood pressure (mmHg) 120.8 (1.5) 120.6 (1.5) ±0.16% (±3.4; 3.2)
Diastolic blood pressure (mmHg) 67.7 (1.0) 68.6 (1.0) 1.3% (±2.8; 5.5)
aAdjusted for age. bSkewed data, therefore geometric mean is shown. *P < 0.05. **P < 0.001.
important confounding factor. In most cross-sec-
tional studies, the study population includes women
in an age-range which encompassed the extreme
ages of menopause [7, 8, 10, 13, 14, 16, 19].
Such a study population comprises premenopausal
women who have irregular menses and postmeno-
pausal women who only recently passed meno-
pause, which decreases the contrast in oestrogen
status between the two groups. On the other hand,
when a large proportion of women is aged in a range
with little overlap between pre- and postmenopausal
women, it is questionable whether age-adjustment
by statistical modelling gives valid results. In some
cross-sectional studies, pre- and postmenopausal
women were matched in categories of age [4, 9,
12]. Within age groups, however, the postmeno-
pausal women are still likely to be older than their
premenopausal counterparts, resulting in residual
confounding. In only one cross-sectional study were
women matched on age in one-year categories [21].
In longitudinal studies, women who went through
menopause during follow-up were compared with
women of the same age who remained pre-
menopausal [5, 6, 17, 32, 33]. These studies
decrease the within-subject variation but at the
expense of contrast in oestrogen status: most
premenopausal women who go through menopause
will have irregular menses at baseline and will only
recently have passed menopause at follow-up. By a
careful matching procedure in the present study, we
composed a population of age-matched pre- and
postmenopausal women.
The women in our study were selected from
responders to a mailed questionnaire. We assume,
however, that the results from our study are
generalizable to the general population even if some
selection has taken place, because we have no
reason to assume that the relationship between
menopause and biological factors will be different in
responders and nonresponders.
To ensure that the results are due to true
associations between natural menopause and cardi-
ovascular risk factors, bias owing to other factors
also has to be considered as a possible explanation.
We excluded women currently using hormone
replacement therapy or oral contraceptives. More-
over, after age-matching and exclusion of women
smoking five cigarettes per day or more, residual
confounding by age, smoking, body mass index and
alcohol drinking habits was dealt with by adjust-
ment in the analyses. Some other determinants of
early menopause were not measured in this study.
For example, socioeconomic status, genetic factors
or parity, may have been related to early menopause
and the difference in lipid levels. This seems unlikely,
however, as although socioeconomic status and
parity have been shown to be associated with
increased lipid levels, the reported effects of these
factors are not large enough to explain the difference
found in our study. Because of our stringent
exclusion criteria, the effect of possible misclassifica-
tion of menopausal status is likely to be small.
Misclassification of age of menopause and number of
postmenopausal years might have occurred, as these
assessments were based on self-reports.
The observation of an increased total cholesterol
level in postmenopausal compared to pre-
menopausal women is in agreement with most
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Fig. 2 Mean lipid levels in 93
premenopausal women and 93
postmenopausal women in three
categories of time since menopause
(,3 years: n = 23; 3±6 years:
n = 39, $6 years:
n = 31).TC = total cholesterol; LDL
C = low density lipoprotein
cholesterol; HDL C = high density
lipoprotein cholesterol;
TG = triglycerides;
Apo = apolipoprotein.
other studies, both cross-sectional [4, 7±10, 12±
16, 26] and longitudinal [5, 6, 11, 17, 32]. We
found age-adjusted levels to be increased by 10.0%;
in other cross-sectional studies the difference ranged
from 8% to 13% [7, 8, 10, 13, 14, 16]. In
accordance with some groups who investigated
linear trends in total cholesterol levels with
postmenopausal years cross-sectionally [4, 8, 13]
or longitudinally [5], we found that these higher
levels were established within the first years after
menopause and did not change thereafter.
The results with respect to LDL cholesterol in our
and other studies are consistent with the findings for
total cholesterol [7, 8, 12±15]. In accordance with
our observation, HDL cholesterol was often found
not to be associated with menopause [8, 10, 12,
14], but in some cross-sectional [9, 13] and
longitudinal studies [17] a slightly lower HDL
cholesterol was found in postmenopausal women.
The apparent inconsistency may be due to small
opposing effects of oestrogen deprivation on the HDL
subfractions [13, 34].
In contradiction to observations in many cross-
sectional studies in which an elevated level of
triglycerides after menopause was found [6, 8,
13, 15, 16], we found no significant difference in
triglycerides between the pre- and postmenopausal
women. We have no explanation for this discre-
pancy. Some other studies, however, including one
cross-sectional and one longitudinal study in which
subjects were matched on age, found no menopau-
sal effect on triglycerides [14, 17, 21].
Few studies examined the relationship between
menopause and apolipoproteins A1 and B. Findings
include a small increase [16], a decrease [7] or no
change [8, 17, 18] in apolipoprotein A1. Apolipo-
protein B, which is a strong marker for coronary
atherosclerosis in women, was increased in
postmenopausal women in some [8, 12, 16, 18],
but not all studies [17]. Our findings that apolipo-
protein A1 was not different and that apolipoprotein
B was higher in post- compared with premenopausal
women is consistent with our observations of the
associated lipoproteins HDL cholesterol and LDL
cholesterol.
Our finding that blood glucose and insulin levels
were not associated with menopause is consistent
with results of other studies [5, 8, 16, 17, 21,
33]. One cross-sectional study did find higher levels
of insulin in postmenopausal women compared to
premenopausal women of the same age [35] and
one longitudinal study found lower levels [26]. Our
finding of comparable insulin levels in pre- and
postmenopausal women does not exclude the
possibility that menopause does have an effect on
glucose metabolism. An increased pancreatic insulin
secretion in postmenopausal women, together with
a compensatory decreased insulin clearance has
been suggested [36]. Two studies have suggested an
age-independent reduction of insulin sensitivity with
time after menopause [37, 38]. In our study we did
not find an increase in insulin levels with time since
menopause.
Although body mass index increases in the
perimenopausal period, body mass index does not
seem to be affected by menopause after adjustment
for age [5, 6, 14, 16, 17, 20]. Data on changes
in fat distribution with menopause are scarce. In a
cross-sectional study the proportion of upper body
fat was higher in women after menopause, but the
results were not adjusted for age [23]. In one small
longitudinal study, central adiposity increased with
menopausal transition, compared to women who
remained premenopausal [32]. In the Healthy
Women's Study, unadjusted differences in waist-to-
hip ratio between pre- and postmenopausal women
were present cross-sectionally, but not longitudin-
ally [24]. The latter finding agrees with our
observation of no difference between the two groups.
Although conflicting results on the relationships
between menopause and blood pressure have been
found, our observation that blood pressure was not
associated with menopause is consistent with most
cross-sectional [9, 14] and longitudinal studies [5,
6, 17]. In most cross-sectional studies only the
diastolic or only the systolic component was affected
by menopause [4, 8, 16, 19]. In a follow-up study,
systolic blood pressure was observed to decline from
2 years before until 6 years after menopause, but no
control group of premenopausal women was present
[20]. One study suggests that menopause affects
stress-induced levels of systolic and diastolic blood
pressure [39].
In conclusion, we selected age-matched pre- and
postmenopausal women, from a large general
population in order to maximize the contrast in
oestrogen status. The results suggest that total
cholesterol, LDL cholesterol and apolipoprotein B
are the primary risk factors affected by menopause.
Because increased cholesterol levels were established
5 2 6 H . W . P E T E R S et al.
# 1999 Blackwell Science Ltd Journal of Internal Medicine 246: 521±528
soon after cessation of menses, preventive measures
aimed at reduction of heart disease in women should
be initiated in early menopause.
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